Navigation Links
GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
Date:3/26/2009

Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April 3. This Section 337 patent dispute (docket# 337-TA-604) was filed against the company by its main competitor, Tate & Lyle Corporation (T&L)

Exeter, California (PRWEB) March 26, 2009 -- Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April 3. This Section 337 patent dispute (docket# 337-TA-604) was filed against the company by its main competitor, Tate & Lyle Corporation (T&L).

"GDFII/L&P was the first company to manufacture sucralose outside of the U.S.A and continues to be committed to meeting its customer needs of high capacity and superior grade sucralose in the growing sucralose market in the United States and elsewhere, and remains confident of a positive outcome once the ITC issues its final determination," notes Mr. Sanyong Wang, a corporate officer of GDFII/L&P.

Mr. Bassam Faress, spokesperson of GDFII/L&P and Director of Sales/Marketing at Ingredients Specialties, Inc., a global alliance partner of GDFII/L&P, adds "we continue to look forward to this anticipated positive final ruling as we move ahead with our strategic marketing and expansion plans for Sucralose."

The U.S. ITC governs investigations into allegations of unfair trade practices and had in its September 2008 initial determination issued by Administrative Law Judge Charles E. Bullock of the ITC, noted that GDFII/L&P has not violated any of the patents asserted in this Section 337 dispute. Furthermore, the Commission found one of the patents asserted by T&L to be invalid. Of the 4 patents asserted by T&L, one of the patents asserted was dropped before the hearing and following an inspection of GDFII/L&P's manufacturing facility; T&L's expert acknowledged that GDFII/L&P Food's current process, as inspected, did not infringe two of the other asserted patents; and a fourth patent expires in July 2009, only a few months after the new target date April 3rd for the ITC's final decision.

Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) is a specialty ingredients manufacturer that pioneered the development and manufacturing of Sucralose at its ISO 9001:2000 and HACCP certified facility in China. In alliance with Ingredient Specialties, Inc. of Exeter, California, provides a global distribution network that markets Züeit ® brand Sucralose to the food, beverage, nutraceutical and pharmaceutical industries as a Kosher and Halal certified non-caloric high intensity sweetener. Züeit ® is a trademark of Ingredient Specialties, Inc. Exeter, CA, U.S.A.

# # #

Read the full story at http://www.prweb.com/releases/sucralose/sweetener/prweb2268614.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Mylan Confirms Four First-to-File Challenges
2. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
3. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
4. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
5. Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
6. Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol
7. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
8. Superior Patient Clinical Outcomes Confirms DaVitas Leadership Position on Quality Dialysis Care
9. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
10. Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg
11. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):